Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias Rummel(Universitätsklinikum Gießen und Marburg), Wolfram Brugger(University of Freiburg), Martina Stauch, Christina Balser(Philipps University of Marburg), Gamal-Andre Banat(Justus-Liebig-Universität Gießen), Ulrich Kaiser(University of Applied Sciences Landshut), Georg Maschmeyer(Radboud University Medical Center), Dorothea Kofahl-Krause(Medizinische Hochschule Hannover), Fritz Roller(Justus-Liebig-Universität Gießen), Axel Hinke, N. Niederle(Klinikum Leverkusen), Harald Balló(Praxis für Hämatologie und Onkologie), Dieter Hoelzer(Endokrinologikum), Juergen Barth(Justus-Liebig-Universität Gießen), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Gerhard Heil(Goethe University Frankfurt), Ulrich von Grünhagen(Praxis für Hämatologie und Onkologie), Christoph Losem, Heinz Dürk(St. Marien Hospital)
Cited by 1,502
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k